What does Ncardia Holding do?

Ncardia Holding is a research organisation in Mont-Saint-Guibert. Public Limited, started on 28 October 2014, 1 establishment.

What is the address of Ncardia Holding?

The registered office of Ncardia Holding is located at Rue Edouard Belin 2, 1435 Mont-Saint-Guibert.

Is Ncardia Holding still active?

Yes. According to the CBE (29 October 2026) Ncardia Holding is active, legal situation “Normale toestand”, started on 28 October 2014.

Is Ncardia Holding registered on Peppol?

Yes, Ncardia Holding is registered on the Peppol network with ID 0208:0565979162.

What is the enterprise number of Ncardia Holding?

The enterprise number of Ncardia Holding is BE0565979162.

When was Ncardia Holding founded?

Ncardia Holding was founded on 28 October 2014.

Who are the directors of Ncardia Holding?

According to the 2025 annual accounts, the directors of Ncardia Holding are: BioPharma Management and Consulting SRL, Nicholas 0'Leary, Geoffrey Glass, Jason Conner, Tim Van Biesen.

Is Ncardia Holding a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 October 2014; 5 annual accounts filed, latest fiscal year 2025; 5 directors known from the annual account.

How much profit did Ncardia Holding make in 2025?

Ncardia Holding recorded a loss after taxes of € 5,677,961 in financial year 2025.

What is the revenue of Ncardia Holding?

As a small company, Ncardia Holding is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -1,468,925.

How many employees does Ncardia Holding have?

According to the 2025 annual accounts, Ncardia Holding has 0 full-time equivalents (FTE).

Ncardia Holding (Public Limited) - Mont-Saint-Guibert

Dossier Ncardia Holding, printed on 29 October 2026 from databakkes.be/en/0565979162/ncardia-holding. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Figures corrected NBB

Corrected annual account filed for 2023, 2024.

Financials

Financial year 2025

Ncardia Holding from Mont-Saint-Guibert, company number BE0565979162, closed financial year 2025 with a result of € -5.7 million after tax. For that financial year Ncardia Holding recorded a gross margin of € -1.5 million and equity of € 98.8 million. Compared with financial year 2024, the result moved from € 1.8 million to € -5.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Healthy

€ 98.8 million

▼ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -5.7 million

▼ still € 1.8 million profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 665,545

▼ 94% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -19.3 million.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Debts at end 2025

Bank debt

€ 6.2 million

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 3 million

▲ 44% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 435,632

▼ 66% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -301,580 Gross margin 2022: € -301,580 First fiscal year in the series	€ -563,631 Gross margin 2023: € -563,631 ▼ € 262,050 vs 2022 (€ -301,580) Unfavourable step	€ -2,151,694 Gross margin 2024: € -2,151,694 ▼ € 1.6 million vs 2023 (€ -563,631) Unfavourable step	€ -1,468,925 Gross margin 2025: € -1,468,925 ▲ € 682,769 vs 2024 (€ -2,151,694) Favourable step	▲ € 682,769
Profit after taxes	€ -267,626 Profit after taxes 2022: € -267,626 First fiscal year in the series	€ 1,694,437 Profit after taxes 2023: € 1,694,437 ▲ € 2 million vs 2022 (€ -267,626) Favourable step	€ 1,757,139 Profit after taxes 2024: € 1,757,139 ▲ 4% vs 2023 (€ 1,694,437) Favourable step	€ -5,677,961 Profit after taxes 2025: € -5,677,961 ▼ € 7.4 million vs 2024 (€ 1,757,139) Unfavourable step	▼ € 7.4 million
Equity	€ 54,326,893 Equity 2022: € 54,326,893 First fiscal year in the series	€ 72,521,330 Equity 2023: € 72,521,330 ▲ 33% vs 2022 (€ 54,326,893) Favourable step	€ 104,501,677 Equity 2024: € 104,501,677 ▲ 44% vs 2023 (€ 72,521,330) Favourable step	€ 98,823,716 Equity 2025: € 98,823,716 ▼ 5% vs 2024 (€ 104,501,677) Unfavourable step	▼ 5%
Total debts	€ 3,568,265 Total debts 2022: € 3,568,265 First fiscal year in the series	€ 3,486,369 Total debts 2023: € 3,486,369 ▼ 2% vs 2022 (€ 3,568,265) Favourable step	€ 3,351,007 Total debts 2024: € 3,351,007 ▼ 4% vs 2023 (€ 3,486,369) Favourable step	€ 9,604,222 Total debts 2025: € 9,604,222 ▲ 187% vs 2024 (€ 3,351,007) Unfavourable step	▲ 187%
Cash	€ 33,156,209 Cash 2022: € 33,156,209 First fiscal year in the series	€ 13,188,118 Cash 2023: € 13,188,118 ▼ 60% vs 2022 (€ 33,156,209) Unfavourable step	€ 10,521,901 Cash 2024: € 10,521,901 ▼ 20% vs 2023 (€ 13,188,118) Unfavourable step	€ 665,545 Cash 2025: € 665,545 ▼ 94% vs 2024 (€ 10,521,901) Unfavourable step	▼ 94%
Retained profit	€ -17,025,966 Retained profit 2022: € -17,025,966 First fiscal year in the series	€ -15,331,529 Retained profit 2023: € -15,331,529 ▲ € 1.7 million vs 2022 (€ -17,025,966) Favourable step	€ -13,574,391 Retained profit 2024: € -13,574,391 ▲ € 1.8 million vs 2023 (€ -15,331,529) Favourable step	€ -19,252,351 Retained profit 2025: € -19,252,351 ▼ € 5.7 million vs 2024 (€ -13,574,391) Unfavourable step	▼ € 5.7 million
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 6,187,871 Bank debt 2025: € 6,187,871 Unchanged (€ 0) Unfavourable step
Balance sheet total	€ 57,895,158 Balance sheet total 2022: € 57,895,158 First fiscal year in the series	€ 76,007,699 Balance sheet total 2023: € 76,007,699 ▲ 31% vs 2022 (€ 57,895,158) Unchanged	€ 107,852,684 Balance sheet total 2024: € 107,852,684 ▲ 42% vs 2023 (€ 76,007,699) Unchanged	€ 108,427,938 Balance sheet total 2025: € 108,427,938 ▲ 1% vs 2024 (€ 107,852,684) Unchanged	▲ 1%

Key figures of Ncardia Holding, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Ncardia Holding?

What happened at Ncardia Holding in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Tim Van Biesen stepped down as director. NBB
2027 BioPharma Management and Consulting SRL stepped down as director. NBB
2027 Nicholas 0'Leary stepped down as director. NBB
2027 Geoffrey Glass stepped down as director. NBB
2027 Jason Conner stepped down as director. NBB
Jun 10, 2026 New annual accounts for financial year 2025: loss of € 5.7 million (▼ € 7.4 million vs 2024). Source: NBB ↗
2026 Jason Conner became a director. NBB
2024 Tim Van Biesen became a director. NBB

In short

From € 267,626 loss in 2022 to € 5.7 million loss in 2025.

Paid € 553,498 in corporate taxes since 2022.

Best year ever: 2024, with € 1.8 million profit.

Original PDFs at the National Bank ↗

Management

Ncardia Holding

NCardia US Inc. 0%

Ncardia B.V. 0%

Cellistic NV 0%

Celyntra Therapeutics 0%

It owns 0% of NCardia US Inc., 0% of Ncardia B.V., 0% of Cellistic NV and 0% of Celyntra Therapeutics itself.

Directors

According to the 2025 annual accounts

BioPharma Management and Consulting SRL

Director · represented by Denis Bedoret

Also active at: EXOTHERA, IMCYSE, BLUE ARMOR

since 2021 · until 2027

Nicholas 0'Leary

Director

since 2021 · until 2027

Geoffrey Glass

Director

since 2021 · until 2027

Jason Conner

Director

Also active at: CELYNTRA THERAPEUTICS, Cellistic

since 2026 · until 2027

Tim Van Biesen

Director

since 2024 · until 2030

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Edouard Belin 2

1435 Mont-Saint-Guibert

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

CELYNTRA THERAPEUTICS same network

€ 560,992 gross margin · 2025

Cellistic same network

€ 8.6 million revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0565.979.162

VAT number

BE 0565.979.162

Registered office

Rue Edouard Belin 2, 1435 Mont-Saint-Guibert

Names & denominations

Ncardia Holding

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 October 2014

Peppol

Active · Active since 2 Dec 2025

Contact

ncardia.com [email protected]

Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Administratieve en ondersteunende activiteiten ten behoeve van kantoren

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige technische testen en toetsen

Overige zakelijke dienstverlening, neg

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

Ncardia Holding

Warning lights

Financials

What happened to Ncardia Holding?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions